WEC
NVAX icon

Winslow Evans & Crocker’s Novavax NVAX Stock Holding History

Winslow Evans & Crocker’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$8K Buy
+75
New +$7.97K ﹤0.01% 995

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Winslow Evans & Crocker's NVAX Position: Q4 2020 in Review

Winslow Evans & Crocker opened a new position in Novavax (NVAX) in Q4 2020: 75 shares worth $8K. The stake represents ﹤0.01% of the portfolio and ranks #995 among its holdings.

347 funds tracked by Wall St. Rank hold NVAX as of Q4 2020.

  • Winslow Evans & Crocker held 75 shares of Novavax worth $8K as of Q4 2020.
  • Novavax was a new Winslow Evans & Crocker position in Q4 2020.
  • Novavax made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #995 holding.
  • 347 funds tracked by Wall St. Rank held Novavax as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.